ABOS SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Acumen Pharmaceuticals Terminates Loan Agreement and Announces 90% Workforce Reduction Amid Strategic Evaluation

Nov 5, 2026

8-K

Acumen Pharmaceuticals Announces Phase 2 ALTITUDE-AD Trial of Sabirnetug Did Not Meet Primary Endpoint; Company to Cease Clinical Development and Explore Strate

Oct 30, 2026

8-K

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

Oct 26, 2026

8-K

Acumen Pharmaceuticals Investor Day Overview: Sabirnetug Phase 2 Results Expected Late 2026

Sep 16, 2026

8-K

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

Aug 12, 2026

8-K

Acumen Pharmaceuticals Nominates Two Enhanced Brain Delivery™ (EBD™) Candidates for Alzheimer’s Disease

Jun 16, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

SHARE RESALE REGISTRATION | Shares: 10,833,331

Apr 1, 2026

424B5

November 2025 ATM | Amount sold to date: $12,300,000

Nov 13, 2025

424B5

SHELF OFFERING | Shares amount: 16,774,193 | Share price: $7.75 | Offering amount: $129,999,996.00

Jul 20, 2023

424B5

SHELF OFFERING | Share price: $6.28 | Offering amount: $100,000,000.00

Jul 17, 2023

424B5

ATM | Offering amount: $50,000,000 | Amount sold to date: $4,246,131

Apr 27, 2023

424B4

OFFERING | Shares amount: 9,999,999 | Share price: $16.00 | Offering amount: $159,999,984.00

Jul 2, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-3

October 2026 SHELF EFFECTIVE, DATED 2026-10-28

Oct 26, 2026

DRS

Form DRS - Draft Registration Statement

Aug 12, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 12, 2026

S-3

SHARE RESALE REGISTRATION

Mar 26, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 26, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 27, 2025

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

S-3

Form S-3 - Registration statement under Securities Act of 1933

Oct 26, 2026

Porter Derrell (Reporting)

Jun 17, 2026

144

Form 144 - Report of proposed sale of securities

Jun 17, 2026

144

Form 144 - Report of proposed sale of securities

Jun 16, 2026

144

Form 144 - Report of proposed sale of securities

Jun 15, 2026

Fountain Nathan B (Reporting)

Jun 10, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 29, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 2, 2026

CORRESP

Form CORRESP - Correspondence

Mar 30, 2026

LETTER

Form UPLOAD - SEC-generated letter

Mar 30, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 25, 2024

CORRESP

Form CORRESP - Correspondence

Apr 22, 2024

Acumen Pharmaceuticals, Inc. ABOS · SEC Filings